• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
What's New in Metastatic Research and Clinical Trials: ER Positive and Triple-Negative Breast Cancer
 

What's New in Metastatic Research and Clinical Trials: ER Positive and Triple-Negative Breast Cancer

on

  • 3,570 views

Slides and audio for this presentation are available on YouTube: http://youtu.be/NJ0HTrH-uog ...

Slides and audio for this presentation are available on YouTube: http://youtu.be/NJ0HTrH-uog

Nancy Lin, MD, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, talks about the differences between various types of breast cancer, and the new therapies that are being developed to treat the disease. This presentation was originally given at the Metastatic Breast Cancer Forum held at Dana-Farber on Oct. 5, 2013. The program was sponsored by EMBRACE (Ending Metastatic Breast Cancer for Everyone).

Statistics

Views

Total Views
3,570
Views on SlideShare
3,327
Embed Views
243

Actions

Likes
1
Downloads
0
Comments
0

2 Embeds 243

https://twitter.com 240
http://www.linkedin.com 3

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Top panel: ductal cancer, lower panel, lobular cancer
  • Mention erica’s trial
  • The vision, then, is that EVERY patient will have his or her tumor biopsied (*) and profiled for relevant DNA alterations (*) to get a somatic mutation signature(*).  That profile will be provided to the oncologist and matrixed together with the repertoire of therapeutic agents (*) to come up with a treatment decision (*)(*) (a decision that is informed by the biology in addition to the anatomic origin of the tumor) 
  • Inhibits binding of androgens to AR, inhibits nuclear translocation of AR, inhibits AR mediated DNA binding
  • LCL161 + taxol for pts with taxane refractory disease
  • LCL161 + taxol for pts with taxanerefractory disease

What's New in Metastatic Research and Clinical Trials: ER Positive and Triple-Negative Breast Cancer What's New in Metastatic Research and Clinical Trials: ER Positive and Triple-Negative Breast Cancer Presentation Transcript